<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03952169</url>
  </required_header>
  <id_info>
    <org_study_id>ProHealth-1</org_study_id>
    <nct_id>NCT03952169</nct_id>
  </id_info>
  <brief_title>Effect of Probiotics on Lipid Management</brief_title>
  <official_title>Role of Probiotics in the Management of Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dysbiosis of gut microbiota has been reported to be involved in the development of
      hypercholesterolemia in both humans and animal models. Probiotics have been reported to have
      ameliorative effects in murine models. However, whether probiotics could help alleviate
      dyslipidemia in adults remain obscure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Probiotics are live microorganisms that have been associated with multiple health benefits.
      However, its protective role in adults has long been controversial. This study aims to
      examine the effect of 12-week probiotics supplementation on lipid management in Chinese
      adults. By understanding the mechanism by which probiotics exert the beneficial effects, we
      can better control the rising prevalence of hypercholesterolemia, which is a major risk
      factor for cardiovascular diseases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2019</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>placebo-controlled, randomized clinical trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participants, investigators and care providers at the scene are all blinded to the allocation of treatment group. Data collected will be analyzed by another investigator who is blinded to the study design.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>baseline, 4 weeks, 8 weeks and 12 weeks</time_frame>
    <description>changes of total cholesterol levels in plasma by automatic biochemical analyzer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>LDL-cholesterol</measure>
    <time_frame>baseline, 4 weeks, 8 weeks and 12 weeks</time_frame>
    <description>changes of LDL-cholesterol levels in plasma by automatic biochemical analyzer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglyceride</measure>
    <time_frame>baseline, 4 weeks, 8 weeks and 12 weeks</time_frame>
    <description>changes of triglyceride levels in plasma by automatic biochemical analyzer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>non HDL-cholesterol</measure>
    <time_frame>baseline, 4 weeks, 8 weeks and 12 weeks</time_frame>
    <description>changes of non HDL-cholesterol levels in plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>gut microbiota</measure>
    <time_frame>baseline, 4 week, 8 weeks and 12 weeks</time_frame>
    <description>changes of gut microbiota by metagenomics</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>blood pressure</measure>
    <time_frame>baseline, 4 week, 8 week and 12 weeks</time_frame>
    <description>changes of blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulse wave velocity</measure>
    <time_frame>baseline and after 12-week intervention</time_frame>
    <description>changes of pulse wave velocity by VP-1000plus from Omron</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ankle Brachial Index</measure>
    <time_frame>baseline and after 12-week intervention</time_frame>
    <description>changes of ankle Brachial Index by VP-1000plus from Omron</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>microbial metabolite</measure>
    <time_frame>baseline and after 12-week intervention</time_frame>
    <description>changes of microbial metabolite by untargeted metabolomics</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Primary Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Probiotics group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be given capsules containing Lactobacillus paracasei once daily for 12 weeks followed by comprehensive physical and clinical examinations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be given capsules containing microcrystalline cellulose once daily for 12 weeks followed by comprehensive physical and clinical examinations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus paracasei dietary supplement</intervention_name>
    <description>a commercial probiotic dietary supplement</description>
    <arm_group_label>Probiotics group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo controls</intervention_name>
    <description>placebo with a similar appearance to probiotics supplement</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible subjects include men and women 18 to 75 years of age with primary
             hypercholesterolemia who has a total cholesterol level of 5.18 mmol/L or higher and/
             or an LDL cholesterol level of 2.59 mmol/L or higher;

          -  Absence of any diet, dietary supplement and medication that might interfere with lipid
             homoeostasis and gut microbiota, especially antibiotics and probiotics.

        Exclusion Criteria:

          -  Triglyceride levels higher than 3.95 mmol/L, or any other systemic, metabolic and
             cardiovascular or cerebrovascular diseases;

          -  Type 1 diabetes, type 2 diabetes treated with insulin or other medications;

          -  Acute illness or current evidence of acute or chronic inflammatory or infective
             diseases;

          -  Participation in any diet or lifestyle program more than 2 times per week in the
             latest 3 months prior to recruitment;

          -  Mental illness rendering them unable to understand the nature, scope, and possible
             consequences of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Xia, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Xia, PhD</last_name>
    <phone>+86 20 87332433</phone>
    <email>xiamin@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yongxin Ye, MBBS</last_name>
    <phone>+86 18820791517</phone>
    <email>931782413@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Nutrition and Food Hygiene</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Xia, PhD</last_name>
      <phone>+86 20 87332433</phone>
      <email>xiamin@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 12, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>May 14, 2019</last_update_submitted>
  <last_update_submitted_qc>May 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Min Xia</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Primary Hypercholesterolemia</keyword>
  <keyword>Probiotics</keyword>
  <keyword>Cardiovascular risk</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

